Yissum Technology Transfer Company of the Hebrew University

24/09/2026

🚀 Your next AI or Quantum collaboration could start here.

We’re excited to launch a new researcher carousel on the Yissum | The Hebrew University Tech Transfer Company homepage, showcasing dozens of researchers working in AI and Quantum at The Hebrew University of Jerusalem!

Why? Because breakthrough research deserves to be discovered. And meaningful collaboration starts with knowing who to connect with.

The carousel puts the people behind the science in the spotlight, helping companies, investors and entrepreneurs explore their research and find potential collaborators.

This launch marks the start of a broader campaign to promote Hebrew University’s AI and Quantum research. We’ll continue to update and expand the carousel, develop complementary content and activities, and promote it across additional channels to reach industry and innovation partners in Israel and around the world.

Our goal: to open doors to new conversations, joint research and commercialization opportunities.

A huge thank you to Auralie Abehssera Hazan, Director of BD at Yissum, for leading the initiative’s content development from the very beginning and helping bring it to life!

🔬 Hebrew University researchers: Working in AI or Quantum and haven’t shared your details yet? Get in touch with Auralie Abehassera Hazan to join the carousel: [email protected]

🤝 Companies, investors and entrepreneurs: Connect directly with researchers to discuss opportunities for collaboration. Our team is here to help turn those first conversations into partnerships.

👉 Visit the Yissum homepage, explore the carousel and meet the researchers: www.yissum.co.il

Discover the research. Meet the people. Let’s explore what we can build together.

🤝Yissum.
Your Innovation. Our Journey. Shared Impact.

17/09/2026

🚀 Dvash Group and The Hebrew University of Jerusalem Partner to Launch Deep-Tech Venture Capital Fund Targeting $50 Million

Dvash Group and The Hebrew University of Jerusalem have announced a strategic partnership to establish a new independent venture capital fund connected to the University’s research and innovation ecosystem. Yissum | The Hebrew University Tech Transfer Company will represent the University in all matters related to the fund.

Managed independently by Dvash Group, led by Yoram Dvash, the fund will initially focus on deep tech, quantum technologies, dual-use technologies, and cybersecurity - fields in which scientific innovation can generate significant commercial and societal impact.

The fund will invest in external deep-tech ventures with significant potential, technologies originating from The Hebrew University of Jerusalem, and startups founded by Hebrew University alumni. It will operate as a private, independent venture capital fund, with investment decisions made independently by the fund’s management.

The partnership is designed to address one of the central challenges in deep-tech innovation: bridging the gap between promising scientific discoveries and the capital, commercial expertise, and industry connections required to turn them into successful companies.

“At Yissum, we see every day the extraordinary potential created by research at the Hebrew University. This partnership connects that research excellence with Dvash Group’s investment leadership, business experience, and international network. Yissum will connect the fund with promising research and commercialization opportunities and help build the relationships needed to advance them from discovery to market", said Alon Natanson, CEO of Yissum.

🔗 Read more: https://lnkd.in/eY9y6JjS

📸 Left to right: Yishai Fraenkel, Meirav Dvash, Barak Ben-Eliezer, Alon Natanson, Tamir Sheafer, Yoram Dvash, Adv. Naama Kaufman-Fass, Ido Gabay, Anat Iosub-Amir, PhD, MBA.

Photo: Bruno Sharvit



Dvash Group
Yissum | The Hebrew University Tech Transfer Company
The Hebrew University of Jerusalem - Europe

15/09/2026

🚀 What if billions of smart devices could operate for years without disposable batteries?

Solra PV, now raising capital through ExitValley, is developing indoor photovoltaic technology designed to turn ordinary room lighting into a continuous source of energy for connected devices.

From sensors and electronic price tags to keyboards, remote controls and smart-building systems, replacing batteries across large IoT networks is expensive, complex and environmentally costly. Solra PV is addressing this challenge at its source.

The company’s patented perovskite solar-cell technology is based on a decade of research by Prof. Lioz Etgar at The Hebrew University of Jerusalem and was commercialized through Yissum | The Hebrew University Tech Transfer Company. It can generate electricity from LED and fluorescent lighting, as well as daylight entering through windows.

According to the company, the technology achieves approximately 20% conversion efficiency under artificial indoor lighting, generates up to four times more electricity than conventional alternatives and can reduce the required solar-cell area by as much as 80%.

This could enable manufacturers to transform everyday connected products into autonomous devices that operate for years with minimal maintenance and without relying on disposable batteries.

Solra PV has already completed a successful proof of concept with MAFAT, Israel’s Directorate of Defense Research & Development, and is advancing pilots and commercial engagements across the defense, industrial, agricultural and consumer sectors.

Behind the technology is a strong scientific and leadership team: Dr. Yosef F***j, CEO and Co-Founder; Dr. Bat-El Cohen Wiezel Weisel, CTO and Co-Founder; and Prof. Lioz Etgar, Chief Scientist and Co-Founder, a globally recognized pioneer in perovskite solar cells at the Hebrew University.

For investors, Solra PV represents an opportunity at the intersection of a rapidly expanding IoT market, advanced materials, scalable manufacturing and the global transition toward more sustainable technology.

📢 For investors seeking differentiated early-stage Deep Tech and CleanTech opportunities, Solra PV is a company worth watching.

🔗 Read more in Globes:
https://lnkd.in/dw_NhaEx

💰 Interested in investing in Solra PV?
Explore the current investment round:
https://lnkd.in/eUJ4YjB4

Photo: Elad Brami



Yissum.
Your Innovation. Our Journey. Shared Impact.

Solra PV
Lioz Etgar
Yosef F***j
Bat-El Cohen Wiezel
Anna Pellivert
Yissum | The Hebrew University Tech Transfer Company
The Hebrew University of Jerusalem - Europe

10/09/2026

May the year ahead turn bold ideas into meaningful impact and shared hopes into a more peaceful future. 🍎🍯
Shana Tova from all of us at Yissum!

The Hebrew University of Jerusalem

08/09/2026

🧬 Yesterday, Yissum | The Hebrew University Tech Transfer Company was proud to take part in the official launch of INBI (Israel National Biotech Innovation Center), designed to unlock Israel’s world-class biomedical research for the development of new therapeutics.

🤝 INBI brings together 15 of Israel’s leading universities, research hospitals, and HMOs with one shared mission: to advance Israel’s life sciences research and bring new medicines to patients in need.

🔬 Created to bridge the translational gap between groundbreaking academic discoveries and attractive therapeutic investment or partnering opportunities, INBI will provide the expertise, infrastructure, networks, capital, and translational capabilities needed to advance promising discoveries toward viable therapeutic programs, companies, and partnerships.

We are proud to join this bold national journey. The work starts now. 🚀

Photographer: Yossi Zwecker

👉 Read more: https://tinyurl.com/y5x5a4ds

The Hebrew University of Jerusalem

06/09/2026

👁️ What if, instead of slowing inherited vision loss, we could correct its genetic cause?

Until recently, that possibility sounded like science fiction. Today, gene therapy, DNA and RNA editing, and personalized medicine are bringing it closer to clinical reality.

Gene therapy already enables physicians to deliver a functioning copy of a defective gene directly into retinal cells. In Israel, infants diagnosed and treated at an early age have begun to see and function better, according to reports from their parents.

And this may be only the beginning.

🔬 Prof. Dror Sharon, Head of the Laboratory for Molecular Ophthalmology at Hadassah Medical Center and The Hebrew University of Jerusalem, is helping advance a new frontier in vision research - one that seeks not merely to slow the loss of sight, but to repair the genetic defect that causes it.

With more than 300 genes associated with inherited retinal diseases, there is unlikely to be one treatment for every patient. The future lies in precision: using gene therapy, CRISPR, DNA and RNA editing, optogenetics and other emerging technologies to develop treatments for specific groups - and potentially even for individual patients.

Research that was considered a dream only a decade ago is now performed routinely in the laboratory and moving closer to clinical trials. 🧬

From uncovering the genetic roots of disease to developing highly personalized treatments, cutting-edge research at The Hebrew University of Jerusalem University is opening new possibilities for people living with inherited vision loss - and bringing genuine hope into sight. ✨

🔗 Read more:
https://tinyurl.com/4cxr4ded



Dror Sharon The Hebrew University of Jerusalem

02/09/2026

🚀 Yissum Insight | H2 2026 is live

Innovation rarely begins with a licensing agreement. It usually begins with a conversation.

The path from discovery to application is built through excellent science, professional expertise, and the right connections.

In our latest issue, discover how Yissum | The Hebrew University Tech Transfer Company is strengthening that path - from intellectual property, licensing and startup creation to earlier engagement with industry, investors, entrepreneurs and international partners.

Inside: The Hebrew University of Jerusalem technologies open for collaboration in AI-powered biomedical prediction, cancer immunotherapy and sustainable agriculture; new platforms connecting research with industry; strategic partnerships extending the reach of Hebrew University innovation; and research moving toward application across health, agriculture, AI, synthetic biology and deep technology.

👉 Read Yissum Insight | H2 2026: https://lnkd.in/d4-PBNnZ

Looking for a technology, research expertise or a new collaboration opportunity? Let’s find the right path forward - together.

Yissum
Your Innovation. Our Journey. Shared Impact.

27/08/2026

🧬 What if programmable RNA could help the immune system see - and fight - cancer that has learned to hide from it?

That is the ambitious idea being advanced by ViVac Pharma, led by CEO Keren Leshem, who is featured on the cover of the August 2026 issue of Visionary Vogues in the story “The Visionary Turning Tomorrow’s Science into Hope for Millions.”

🔬 ViVac is developing next-generation RNA immunotherapies that combine synthetic biology with lipid nanoparticle delivery. Its platform is designed to deliver self-limiting, virus-like instructions directly into tumors, triggering a powerful but controlled localized immune response to help the body recognize and attack ovarian cancer and other solid tumors more effectively.

The company, built on pioneering research from The Hebrew University of Jerusalem laboratories of Prof. Lior Nissim and Prof. Chezy Barenholz, is currently at the preclinical proof-of-concept stage. ViVac reports validation in vitro and confirmation of RNA expression and tumor-targeted delivery in vivo as it works to advance its programs toward clinical development.

🚀 This progress is also reflected in ViVac’s recent selection to advance in the FY26 U.S. Department of Defense Ovarian Cancer Research Program, a highly competitive program supporting innovative research with the potential to improve outcomes for women with ovarian cancer.

As ViVac prepares for the program’s next phase, it is working alongside experienced ovarian cancer patient advocates so that patient perspectives can help shape the research from its earliest stages - bringing scientists, clinicians and patients together around the shared goal of developing better treatment options.

The cover story goes beyond the science. It follows Keren’s three-decade journey across biotechnology, pharmaceuticals, medical devices, diagnostics and women’s health - and explores the leadership required to turn breakthrough research into solutions that can ultimately reach patients.

💡 It highlights a philosophy built on purpose, resilience, collaboration and adaptability: remain committed to the mission, bring exceptional people together, and be willing to change the strategy as the evidence evolves.

👏 Warm Congratulations to Keren and the entire ViVac Pharma team on this well-deserved recognition. We are proud to see bold science originating at the Hebrew University being led forward with the ambition, experience and humanity required to pursue meaningful patient impact.

🔗 Read the full cover story: https://tinyurl.com/474sfcc7



The Hebrew University of Jerusalem ליאור ניסים

18/08/2026

🔬 If commercialization begins long before a technology is ready for market, where should the role of a technology transfer organization begin?

Alon Natanson, CEO of Yissum, and Gady Paran, Director of Marketing at Yissum, have published a new opinion piece in The Jerusalem Post, “The Next Evolution of Technology Transfer,” exploring the evolving role of technology transfer organizations in a changing innovation landscape.

As stated in the article, the core mission remains clear: intellectual property management, licensing and startup creation remain the foundation of technology transfer.

But commercialization often begins much earlier, through relationships, conversations and collaborations that can start long before a technology is ready for commercialization.

🤝 Drawing on Yissum’s experience over the past year, the article explores three complementary approaches: encouraging earlier dialogue between researchers and industry, strengthening collaboration between academic institutions, and bringing together the broader innovation community.

“Technology transfer organizations do not need a new mission. They need a broader view of how that mission succeeds.”

🌐 Looking further ahead, the article suggests:
“The organizations that create the greatest long-term impact may be those that also invest in something less tangible: the ecosystems that enable greater commercialization.”

➡️ Commercialization remains the destination. Building the conditions that allow more discoveries to reach that destination may become one of the defining responsibilities of technology transfer in the years ahead.

We hope the article contributes to the ongoing professional conversation about the future of technology transfer and how stronger connections across academia, industry, entrepreneurship and investment can help more discoveries move from research to impact.

📖 Read the full article in The Jerusalem Post:
https://tinyurl.com/yj8kjcnh

We invite you to read, share and continue the conversation with colleagues, partners and professional communities across the global innovation and technology transfer ecosystem.

Gady Paran The Hebrew University of Jerusalem

Today’s scientific breakthroughs rarely emerge in isolation. They are increasingly shaped by collaboration across disciplines, institutions, and sectors.

16/08/2026

🌍 #89 WORLDWIDE | Hebrew University of Jerusalem | Shanghai Ranking 2026

World-class research is where world-changing innovation begins.

The Hebrew University of Jerusalem has been ranked 89th among the world’s top 100 universities in the 2026 Shanghai Ranking (ARWU), reaffirming its place among the world’s leading academic and research institutions.

This year, two Israeli institutions are represented in the global top 100:
🇮🇱 Weizmann Institute of Science - #71
🇮🇱 The Hebrew University of Jerusalem - #89

Published annually since 2003, the Shanghai Ranking evaluates more than 2,500 universities worldwide, with a strong focus on research excellence and academic impact.

At Yissum | The Hebrew University Tech Transfer Company, we have the privilege of seeing where this research excellence can lead.

Every discovery holds the potential to become something more: a new technology, an industry collaboration, a startup, or a solution to a global challenge.

Today, we celebrate the researchers, faculty, students and entire Hebrew University community whose excellence makes achievements like this possible. Congratulations! 👏

As we look toward the 2026 - 2027 academic year, we look forward to the discoveries still to come, and to helping translate outstanding research into innovation and impact far beyond the university.



ShanghaiRanking Weizmann Institute of Science The Hebrew University of Jerusalem